Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
35 results about "Collagen-induced arthritis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Collagen-induced arthritis (CIA) is a condition induced in mice (or rats) to study rheumatoid arthritis. CIA is induced in mice by injecting them with an emulsion of complete Freund's adjuvant and type II collagen.
Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound
InactiveCN106432249AGood choiceApparently irreversible inhibitionOrganic chemistryAntipyreticSynthesis methodsProliferation activity
The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.
![Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound](https://images-eureka.patsnap.com/patent_img/ea4c1d28-2148-4b87-a68d-452b0c5666ca/160929161714.png "Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound")
![Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound](https://images-eureka.patsnap.com/patent_img/ea4c1d28-2148-4b87-a68d-452b0c5666ca/160929161717.png "Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound")
![Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound](https://images-eureka.patsnap.com/patent_img/ea4c1d28-2148-4b87-a68d-452b0c5666ca/160929161720.png "Synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound")
Owner:NINGBO WESDON POWDER PHARMA COATINGS CO LTD
Application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis
InactiveCN102499916AOrganic active ingredientsAntipyreticOrally disintegrating tabletInterferon alpha
The invention provides application of 1 beta-hydroxy alantolactone in preparation of medicine for preventing and curing rheumatoid arthritis. The structural formula of the 1 beta-hydroxy alantolactone is as follows: the 1 beta-hydroxy alantolactone is used for carrying out animal pharmaceutical effect tests, and results show that the 1 beta-hydroxy alantolactone obviously suppresses attack severity and morbidity of CIA (collagen-induced arthritis). TNF-alpha (tumor necrosis factors alpha), IL-17 (interleukin 17) and IFN-gamma (interferon gamma) in supernate of splenocyte can be reduced, secretion of proinflammatory cytokine TNF-alpha, IFN-gamma and IL-17 is suppressed, and accordingly CIA diseases are prevented. Accordingly, the application can be used for preparing medicine for treating rheumatoid arthritis. Medicine composition in the invention is prepared by the 1 beta-hydroxy alantolactone used as active ingredients and conventional medicine carriers and can be prepared into tablets, dispersible tablets, lozenge, orally disintegrating tablets, sustained-release tablets, capsules, soft capsules, dropping pills, granular formulation, injection, powder injection or aerosol and the like. The application has great clinical application values.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Application of berberine in preparing medicament for preventing and treating rheumatoid arthritis
InactiveCN101822670AOrganic active ingredientsAntipyreticOrally disintegrating tabletTumor necrosis factor alpha
The invention provides application of berberine in preparing a medicament for preventing and treating rheumatoid arthritis. When the berberine is adopted for animal effectiveness test, results show that the berberine can inhibit clinical morbidity of collagen-induced arthritis, and obviously inhibit serious morbid degree and morbidity. The berberine can downwards regulate tumor necrosis factor alpha, interleukin 17 and interferon gamma in splenocyte supernate, and inhibit the secretion of proinflammatory cytokines TNF-alpha, IFN-gamma and IL-17 so as to prepare the medicament for preventing and treating the rheumatoid arthritis with great clinical application value. The medicament is a medicinal composition prepared from the berberine serving as an active ingredient and conventional pharmaceutical adjuvant, and comprises tablets, dispersible tablets, buccal tablets, orally disintegrating tablet, sustained release tablets, capsules, soft capsules, pills, granules, injection, powder injection or aerosol.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Therapeutic uses of glandular kallikrein
InactiveUS20070224209A1Lower immune responsePeptide/protein ingredientsSnake antigen ingredientsDiseaseGlandular Kallikrein
An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Further experiments revealed that the excision of SMG (SMGx) from Lewis rats prevents the oral induction of immunological tolerance against native bovine type II collagen (BCII). Thus SMGx rats, when they were given oral BCII and were subsequently immunized with the same antigen, developed collagen induced arthritis (CA), while normal rats given an identical treatment were protected from the disease. When SMGx rats were orally given porcine K1 in conjunction with BCII, the capacity of such animals to develop oral tolerance was fully restored. These results indicate that normal SMG function is required for induction of oral tolerance and that K1 is involved in mediating this function.
Owner:DIAMEDICA INC
Polypeptide for inhibiting joint inflammations in mice and application thereof
InactiveCN109251237AReduce morbidityRelieve symptomsPeptide/protein ingredientsAntipyreticAntigenJoints inflammation
The invention discloses a polypeptide for inhibiting joint inflammations in mice and application thereof. The micro-molecule polypeptide SJMHE1 originated from the egg and imago antigens of Schistosoma japonicum consists of 24 amino acids, is a T cell epitope shared by human and mouse HSP60 molecules, and can prevent and treat collagen-induced arthritis in mice. The polypeptide of the invention has the beneficial benefits that the polypeptide can be used for treating rheumatoid arthritis and has potential new drug development value.
Owner:AFFILIATED HOSPITAL OF JIANGSU UNIV
Application of traditional Chinese medicine huanglian jiedu tang in preparing medicament for preventing and treating rheumatoid arthritis
InactiveCN101653502AOvercoming toxic effectsTreatment confidenceAntipyreticAnalgesicsDiseaseSide effect
The invention provides an application of a traditional Chinese medicine huanglian jiedu decoction (comprising the Chinese medicine components of 9g of coptis chinensis, 6g of scutellaria baicalensis,6g of golden cypress and 9g of gardenia) in preparing a medicament for preventing and treating rheumatoid arthritis. When being used for animal pharmacodynamic test, the huanglian jiedu decoction is proved to have the functions of restraining the clinical pothogenesy of CIA (Collagen-Induced Arthritis), obviously restraining the severity and the morbidity of the CIA and having obvious protection function to the CIA. The huanglian jiedu decoction can reduce the contents of TNF-alpha, IL-17 and IFN-gamma in splenocyte supernatant and restrain the secretion of proinflammatory cytokine, i.e. TNF-alpha, IFN-gamma and IL-17, thereby playing a protecting role for the CIA disease. The invention provides a new traditional Chinese medicine for clinically treating rheumatoid arthritis, which can overcome the toxic and side effects of pharmaceutical chemicals, thereby bringing confidence for treating and achieving higher clinical application value.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Model animal with favorite onset or rheumatoid arthritis
The present invention provides a model animal with favorite onset of rheumatoid arthritis wherein the severity of arthritis reaches the maximum level and its onset ratio is a hundred percent, and a screening method of a remedy for rheumatoid arthritis by using the model animal. A mouse whose function of immunoglobulin Fcγ receptor IIB gene is deficient on its chromosome and a wild-type collagen-induced arthritis-susceptible DBA / 1J mouse are backcrossed six times or more, and a model mouse with favorite onset of rheumatoid arthritis is constructed. This model mouse with favorite onset of rheumatoid arthritis is immunized with bovine joint-origin type II collagen to develop collagen-induced arthritis.
Owner:JAPAN SCI & TECH CORP
Preparation method, application and evaluation method of collagen-induced arthritis animal model
The invention provides a preparation method of a collagen-induced arthritis animal model. The method includes the steps that 6-8 week old male DBA / 1 mice are selected; the mice selected in step (1) are placed and raised in a clean animal room where the temperature is 20-24 DEG C, the humidity is 50%-60%, and light and dark are alternating every 12 hours, the mice are free to take food and drink water, and after three days of acclimatization the mice are used for preparing the model; a chicken type-II collagen is used for immunizing the DBA / 1 mice to induce the CIA model, and the mice are immunized by intradermal injection into the tail bases of the mice; three immunizations are conducted. The method is of great significance for the pathological mechanism study and drug development of arthritis. Meanwhile, an evaluation method of the collagen-induced arthritis animal mode, through arthritis clinical index grading, ankle joint pathology examination, and determination of serum anti-CII-IgG antibody level and other indicators, is used for verifying whether the model is successful and comprehensively evaluating the collagen-induced arthritis animal model.
Owner:NANTONG UNIVERSITY
Biaryl urea carboxylic acid derivative or salt as well as preparation method and application thereof
ActiveCN107522634AInhibitory receptorInhibitionNervous disorderOrganic chemistryMS multiple sclerosisT protein
The invention belongs to the technical field of chemical medicines and relates to a biaryl urea carboxylic acid derivative or a salt of the compound of formula I, as well as a preparation method, a medicinal composition and application of the compound in preparing medicines for treating diseases related to RORgamma t. Study results show that the compound can effectively inhibit RORgamma t protein receptors, so that differentiation of Th17 cells can be regulated and controlled, generation of IL-17 can be inhibited, treatment medicines for inflammation related diseases mediated by RORgamma t can be further prepared, and inflammation related diseases such as disseminated sclerosis, rheumatoid arthritis, collagen-induced arthritis, psoriasis, inflammatory bowel diseases, encephalomyelitis, clone diseases, asthma and cancer can be treated. The formula I is as shown in the specification.
Owner:FUDAN UNIV
Methods of treatment involving p21/CIP1
InactiveUS20080226599A1Inhibit aberrant growthInhibit inflammationBiocideCompound screeningDiseaseAdjuvant arthritis
The onset ratios and pathological conditions of collagen-induced arthritis and adjuvant arthritis in model mice and rats, respectively, were successfully ameliorated by topically expressing the cyclin-dependent kinase inhibitors p16INK4a and p21Cip1 p in articular tissues using adenoviral vectors. In the synovial cells of CDKI-transduced mice, expression of inflammatory cytokines was inhibited. Described are the use of the p21Cip1 protein for inhibiting abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or expression of inflammatory cytokines in synovial tissues; the p21Cip1 gene; compounds promoting the activity or expression of the p21Cip1 protein; and pharmaceutical compositions containing these molecules. Also provided are method of screening for compounds participating in the abnormal proliferation of synovial tissues, inflammation in synovial tissues and / or the expression of inflammatory cytokines in synovial tissues targeting the p21Cip1 protein. Rheumatoid arthritis and other disorders associated with inflammation of the synovial tissue can be prevented or treated by promoting expression or function of p21Cip1 protein.
Owner:MIYASAKA NOBUYUKI +1
Myricaria germanica effective part, preparation method and use thereof
The invention relates to a Myricaria germanica effective part, a preparation method and use thereof in treatment of rheumatism and rheumatoid arthritis. Animal experiments prove that the effective part can inhibit croton oil induced mouse ear swelling and rat adjuvant or collagen induced arthritis, and can be used for prevention and / or treatment of rheumatism and rheumatoid arthritis.
Owner:INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Liposome dimethylcurcumin inhibits activities of dipeptidase I and matrix metalloproteinase-9
The liposome dimethylcurcumin is a liposome-encapsulated dimethylcurcumin (Lipo-DiMC). Dimethyl curcumin is a synthetic curcumin analog with the chemical formula C23H24O6. Compared with curcumin and dimethyl curcumin, Lipo- DiMC has better metabolic stability and is highly water soluble and has a sustained release effect in vivo. In some inflammatory, autoimmune and cancer diseases, Dipeptidyl peptidase (DPPI) and Matrix metalloproteinase (9, MMP-9) are overexpressed, leading to changes in tissue microenvironment and in vivo. Balance disorders and cause cell reproductive disorders. In the ratmodel of collagen induced arthritis (CIA) treated with Lipo-DiMC, Lipo-DiMC alleviated the swelling of the toes of CIA rats and inhibited DPPI and MMP in body fluids, blood and spleen lymphocytes of CIA rats-9 Overexpression of activity. The in vitro rat spleen lymphocyte model further confirmed that Lipo-DiMC inhibited and regulated the DPPI activity and MMP 9 expression and secretion in rat spleen lymphocytes.
Owner:CHANGZHOU UNIV
Total lignan extract of stalkedfruit pricklyash bark for treating arthritis
ActiveCN102091161ASmall side effectsWay to increaseSkeletal disorderPlant ingredientsSide effectLignan
The invention discloses a total lignan extract of stalkedfruit pricklyash bark, which is characterized in that the content of total lignan is above 30%. The total lignan extract of stalkedfruit pricklyash bark is extracted and refined from the traditional Chinese medicine stalkedfruit pricklyash bark. Proven by pharmacodynamical and toxicological tests, the total lignan extract of stalkedfruit pricklyash bark can obviously improve the collagen induced arthritis of rats, and simultaneously has better analgesis and anti-inflammation effects with small toxic side effects. The invention also discloses a medical application of the total lignan extract of stalkedfruit pricklyash bark.
Owner:湖南药圣堂中药科技有限公司
Biaryl urea derivative as well as salt, preparation method and application thereof
ActiveCN107522641AInhibitory receptorRegulation of differentiationNervous disorderOrganic chemistryMS multiple sclerosisInflammatory bowel disease
The invention belongs to the technical field of chemical medicines and relates to a biaryl urea derivative of formula I with RORgamma t inhibition activity, a preparation method of the derivative, and application of the derivative in preparing medicines for treating diseases related to RORgamma t. Tests show that the biaryl urea derivative can effectively inhibit RORgamma t protein receptors, so that differentiation of Th17 cells can be regulated and controlled, generation of IL-17 can be inhibited, treatment medicines for inflammation related diseases mediated by RORgamma t can be further prepared, and inflammation related diseases such as disseminated sclerosis, rheumatoid arthritis, collagen-induced arthritis, psoriasis, inflammatory bowel diseases, encephalomyelitis, clone diseases, asthma and cancer can be treated. The formula I is as shown in the specification.
Owner:FUDAN UNIV
Application of CXCL8-CXCR1 of tree shrew in treatment of rheumatoid arthritis
InactiveCN105061582AReduce inflammationPeptide/protein ingredientsAntipyreticChemokine Receptor GeneInhibitory receptors
The invention identifies a chemotactic factor CXCL8 gene and a chemokine receptor CXCR1 gene of a tree shrew and proteins encoded by the two genes, and determines that a signal path formed by CXCL8 and CXCR1 participates in adjustment of peripheral blood lymphocyte migration functionally. In a tree shrew CIA (collagen induced arthritis) animal model, reduction of the concentration of CXCL8 in peripheral blood or inhibition of the function of the receptor CXCR1 can effectively reduce migration of immune lymphocyte cells to peripheral bones and joints, and the effect of treatment of rheumatoid arthritis is achieved. A therapeutic molecular target is provided for a patient suffering from clinic rheumatoid arthritis.
Owner:YUNNAN UNIV
Cortex zanthoxyli total alkaloid extract and preparations as well as application thereof
InactiveCN104587026APrevent proliferationEnsure safetyAntipyreticAnalgesicsJoint synovialSide effect
The invention provides a cortex zanthoxyli total alkaloid extract and preparations as well as application thereof. The cortex zanthoxyli total alkaloid extract is obtained by extraction from the traditional Chinese medicine cortex zanthoxyli, and refining, wherein the total alkaloid content is basically more than 50%, and is up to 100% in maximum. The invention further provides preparations and medical application of the cortex zanthoxyli total alkaloid extract, wherein the preparations include powder injection, dropping pills, tablets, capsules, granules, and so on. Pharmacodynamic and toxicology tests prove that the cortex zanthoxyli total alkaloid extrac can remarkably restrain proliferation of CIA (Collagen Induced Arthritis) rat joint synovial cells, and has low toxic and side effects.
Owner:HUNAN UNIV OF CHINESE MEDICINE
Application of general inula helenium sesquiterpene lactone in preparation of medicine for treating rheumatoid arthritis
ActiveCN103251667BConvenient sourceSignificant effectOrganic active ingredientsAntipyreticAdditive ingredientHelenium
The invention provides application of general inula helenium sesquiterpene lactone in preparation of a medicine for treating rheumatoid arthritis. The general inula helenium sesquiterpene lactone contains alantolactone and isoalantolactone; and the sum of the contents of the alantolactone and the isoalantolactone accounts for 60 to 90%. The results of animal pharmacodynamic tests show that the general inula helenium sesquiterpene lactone, the alantolactone and the isoalantolactone all can inhibit the clinical onset of CIA (Collagen-induced Arthritis), obviously inhibit the morbidity of CIA, obviously reduce the level of IFN(Interferon)-gamma, and remarkably inhibit the generation of IL(Interleukin)-17. Therefore, the general inula helenium sesquiterpene lactone, the alantolactone and the isoalantolactone all can be used for preparing the medicine for treating rheumatoid arthritis. The medicine is composed of the general inula helenium sesquiterpene lactone serving as an active ingredient and a pharmaceutic adjuvant and can be in form of a troche, a capsule, a soft capsule, a dropping pill, granules, an injection, a powder-injection or an aerosol and the like. The medicine provided by the invention is a new medicine for treating rheumatoid arthritis, which has remarkable curative effect and little side reaction; the raw materials are conveniently obtained, the preparation method is simple, and the medicine has relatively high clinical application value.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
METHODS OF TREATMENT INVOLVING p21/CIP1
InactiveUS20100310508A1Avoid overgrowthEfficient screeningOrganic active ingredientsPeptide/protein ingredientsDiseaseSynovial Cell
Owner:MIYASAKA NOBUYUKI +1
Application of Pianzaihuang for preparing medicine capable of treating rheumatoid arthritis
InactiveCN110638851ARare side effectsImprove securityAntipyreticAnalgesicsInflammatory factorsMethotrexate
The invention discloses application of Pianzaihuang for preparing a medicine capable of treating rheumatoid arthritis. A collagen induced arthritis mouse model is adopted to prove that the Pianzaihuang can obviously improve a CIA (collagen induced arthritis) mouse arthritis index, improve a mouse ankle joint pathological index and obviously lower mouse serum inflammatory factor expression. The treatment effect of the Pianzaihuang is equivalent to the treatment effect of a positive medicine-methotrexate, and in addition, safety is good so as to point out that the Pianzaihuang has a clinic valuethat the Pianzaihuang can be applied to the treatment of the rheumatoid arthritis.
Owner:ZHANGZHOU PIEN TZE HUANG PHARM
Carbazole amide derivatives or salts thereof, preparation method and use thereof
The present invention discloses a novel carbazole amide derivative or its salt represented by the general formula I with RORγt activity regulating effect and a preparation method thereof, and also discloses the use of the carbazole amide derivative or its salt in preparing therapeutic Use in medicine for diseases associated with RORγt. Experimental results show that the carbazole amide derivatives of the present invention or their salts can effectively regulate the activity of RORγt protein receptors, thereby regulating the differentiation of Th17 cells and the production of IL-17, and further serve as therapeutic drugs for the treatment of related diseases mediated by RORγt , especially for the treatment of multiple sclerosis, rheumatoid arthritis, collagen-induced arthritis, psoriasis, inflammatory bowel disease, encephalomyelitis, clonal disease, asthma and various cancers and other related diseases.
Owner:FUDAN UNIV
Artemisia japonica homogeneous polysaccharides as well as preparation method and application thereof
ActiveCN105949336AHigh purityReduce foot swellingOrganic active ingredientsAntipyreticChromatographic separationInflammatory factors
The invention discloses Artemisia japonica homogeneous polysaccharides as well as a preparation method and an application thereof. The Artemisia japonica homogeneous polysaccharides are obtained through column chromatographic separation and purification after water extraction and alcohol precipitation of all grass of Artemisia japonica, are inulin type fructan which is connected by fructose through 1,2 and contains a glucosyl group at the terminal, contain no uronic acid and have the weight-average molecular weight ranging from 1 kDa to 20 kDa. Experiment results indicate that the Artemisia japonica homogeneous polysaccharides can obviously reduce the foot swelling degree of mice suffering from collagen-induced arthritis and levels of inflammatory factors IL-6 and IL-17A in serum of the mice, are expected to be used as a major or unique active ingredient for preparation of health-care food or pharmaceutic preparations for preventing or / and treating rheumatoid arthritis, and have the important significance in research and development of Artemisia japonica pharmaceutic preparations having the clinical application value; besides, the preparation method is simple, high-purity Artemisia japonica homogeneous polysaccharides can be obtained, and the method is suitable for large-scale production and good in practicability.
Owner:SHANGHAI UNIV OF T C M
Application of kaempferol in preparation of medicine for rheumatoid arthritis
InactiveCN109172565AExcellent anti-rheumatoid arthritis effectOrganic active ingredientsAntipyreticIntraperitoneal routeLeflunomide therapy
The invention discloses the application of kaempferol in preparation of medicine for rheumatoid arthritis, especially oral administration, has excellent anti-rheumatoid arthritis effect, The effects of kaempferol on arthritis induced by collagen were studied by gastric perfusion and intraperitoneal injection. The effects of kaempferol on arthritis induced by collagen were studied, It was found that kaempferol had protective effect on collagen-induced arthritis model mice, and the effect was better than that of intraperitoneal administration, which was equivalent to the effect of leflunomide, apositive drug. It provided a optimal drug for clinical treatment of rheumatoid arthritis and related autoimmune diseases.
Owner:CHINA PHARM UNIV
Compound and application thereof in preparation of medicines for preventing/treating autoimmune diseases
InactiveCN107880043AImprove targetingEasy to operateOrganic chemistryAntipyreticImmunologic disordersMedicine
The invention discloses a compound formula (I), wherein R is selected from or. The compound formula (I) of the present invention can inhibit the production of IL-12 in vitro, has an inhibitory effect on the proliferation of HaCat cells, and exhibits excellent activity in the SD rat collagen-induced rheumatoid arthritis model. It shows that the compound formula (I) of the present invention can be used as a candidate drug for the prevention / treatment of autoimmune diseases for further research and development.
Owner:田甜
Bridged ring piperazine derivatives or salts thereof, preparation method and use thereof
ActiveCN109134476BInhibitory receptorInhibitionOrganic active ingredientsNervous disorderReceptorBowels diseases
Owner:FUDAN UNIV
Application of low-molecule heparin in medicament preparation
InactiveCN101780101AInhibit rheumatoid synovial inflammationInhibition of adhesionOrganic active ingredientsAntipyreticDiseaseInflammatory cell
The invention discloses the application of low-molecule heparin in preparing medicaments for treating collagen-induced arthritis. The invention provides the application of the low-molecule heparin in preparing the medicaments for treating rheumatic diseases, wherein the rheumatic disease are chronic infectious arthritis. The invention has the advantages of exploring the purpose medical treatment of the low-molecule heparin and developing a new application field. The result indicates that the low-molecule heparin has the function of restraining the synovium inflammation of the chronic infectious arthritis and has one of purposes of restraining the adhesion of synovial fibroblast cells and inflammatory cells. The result provides the experimental basis for seeking biological treating target spots and other small-molecule treating target sports, and the low-molecule heparin has clinical application values.
Owner:上海市长宁区光华中西医结合医院
Synthesis and medical application of a kind of pyrrolo[2,1-f][1,2,4]triazine core compound
InactiveCN106432249BGood choiceApparently irreversible inhibitionOrganic chemistryAntipyreticAnti arthriticSynthesis methods
The invention discloses a synthesis and medical application of pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound. The compound belongs to a novel-structure compound. The synthesis method is high in operating safety, mild in reaction condition and suitable for industrial production. The activity and the selectivity of BTK kinase and the in-vitro proliferation activity of a leukemia cell line are test, it is verified that the compound has the selective and irreversible inhibition effect on the BTK kinase, and has the different-degree inhibition effect on leukemia cells. According to measurement, the compound also has the good anti-arthritic activity on a collagen-induced arthritis (rCIA) model. The pyrrolo-[2,1-f] [1,2,4] triazine mother nucleus compound can be used for preparing medicine for treating arthritis and leukemia.
![Synthesis and medical application of a kind of pyrrolo[2,1-f][1,2,4]triazine core compound](https://images-eureka.patsnap.com/patent_img/62895a3b-17ae-4bd1-b3c1-b7b69c9e28d7/160929161714.png "Synthesis and medical application of a kind of pyrrolo[2,1-f][1,2,4]triazine core compound")
![Synthesis and medical application of a kind of pyrrolo[2,1-f][1,2,4]triazine core compound](https://images-eureka.patsnap.com/patent_img/62895a3b-17ae-4bd1-b3c1-b7b69c9e28d7/160929161717.png "Synthesis and medical application of a kind of pyrrolo[2,1-f][1,2,4]triazine core compound")
![Synthesis and medical application of a kind of pyrrolo[2,1-f][1,2,4]triazine core compound](https://images-eureka.patsnap.com/patent_img/62895a3b-17ae-4bd1-b3c1-b7b69c9e28d7/160929161720.png "Synthesis and medical application of a kind of pyrrolo[2,1-f][1,2,4]triazine core compound")
Owner:NINGBO WESDON POWDER PHARMA COATINGS CO LTD
Total lignan extract of stalkedfruit pricklyash bark for treating arthritis
ActiveCN102091161BSmall side effectsWay to increaseSkeletal disorderPlant ingredientsSide effectLignan
The invention discloses a total lignan extract of stalkedfruit pricklyash bark, which is characterized in that the content of total lignan is above 30%. The total lignan extract of stalkedfruit pricklyash bark is extracted and refined from the traditional Chinese medicine stalkedfruit pricklyash bark. Proven by pharmacodynamical and toxicological tests, the total lignan extract of stalkedfruit pricklyash bark can obviously improve the collagen induced arthritis of rats, and simultaneously has better analgesis and anti-inflammation effects with small toxic side effects. The invention also discloses a medical application of the total lignan extract of stalkedfruit pricklyash bark.
Owner:湖南药圣堂中药科技有限公司
Carbazolamide derivatives or salts thereof, and preparation method and use thereof
The invention discloses new carbazolamide derivatives or salts thereof having ROR[gamma]t activity regulating effect and represented by the general formula I and a preparation method thereof, and alsodiscloses a use of the carbazolamide derivatives or the salts thereof in preparation of drugs for treating ROR[gamma]t related diseases. Experimental results indicate that the carbazolamide derivatives or the salts thereof can effectively regulate the activity of a ROR[gamma]t protein receptor so as to regulate the differentiation of Th17 cells and the production of IL-17, further serves as treatment drugs for treating ROR[gamma]t-mediated related diseases, especially is suitable for treatment of multiple sclerosis, rheumatoid arthritis, collagen-induced arthritis, parapsoriasis guttata, inflammatory bowel disease, encephalomyelitis, clonal diseases, asthma, various cancers and other related diseases.
Owner:FUDAN UNIV
Application of traditional Chinese medicine huanglian jiedu tang in preparing medicament for preventing and treating rheumatoid arthritis
InactiveCN101653502BOvercoming toxic effectsTreatment confidenceAntipyreticAnalgesicsSide effectArthritis- rheumatoid arthritis
The invention provides an application of a traditional Chinese medicine huanglian jiedu decoction (comprising the Chinese medicine components of 9g of coptis chinensis, 6g of scutellaria baicalensis, 6g of golden cypress and 9g of gardenia) in preparing a medicament for preventing and treating rheumatoid arthritis. When being used for animal pharmacodynamic test, the huanglian jiedu decoction is proved to have the functions of restraining the clinical pothogenesy of CIA (Collagen-Induced Arthritis), obviously restraining the severity and the morbidity of the CIA and having obvious protection function to the CIA. The huanglian jiedu decoction can reduce the contents of TNF-alpha, IL-17 and IFN-gamma in splenocyte supernatant and restrain the secretion of proinflammatory cytokine, i.e. TNF-alpha, IFN-gamma and IL-17, thereby playing a protecting role for the CIA disease. The invention provides a new traditional Chinese medicine for clinically treating rheumatoid arthritis, which can overcome the toxic and side effects of pharmaceutical chemicals, thereby bringing confidence for treating and achieving higher clinical application value.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
A kind of Artemisia annua homogeneous polysaccharide and its preparation method and application
ActiveCN105949336BHigh purityReduce foot swellingOrganic active ingredientsAntipyreticHomopolysaccharideInflammatory factors
The invention discloses Artemisia japonica homogeneous polysaccharides as well as a preparation method and an application thereof. The Artemisia japonica homogeneous polysaccharides are obtained through column chromatographic separation and purification after water extraction and alcohol precipitation of all grass of Artemisia japonica, are inulin type fructan which is connected by fructose through 1,2 and contains a glucosyl group at the terminal, contain no uronic acid and have the weight-average molecular weight ranging from 1 kDa to 20 kDa. Experiment results indicate that the Artemisia japonica homogeneous polysaccharides can obviously reduce the foot swelling degree of mice suffering from collagen-induced arthritis and levels of inflammatory factors IL-6 and IL-17A in serum of the mice, are expected to be used as a major or unique active ingredient for preparation of health-care food or pharmaceutic preparations for preventing or / and treating rheumatoid arthritis, and have the important significance in research and development of Artemisia japonica pharmaceutic preparations having the clinical application value; besides, the preparation method is simple, high-purity Artemisia japonica homogeneous polysaccharides can be obtained, and the method is suitable for large-scale production and good in practicability.
Owner:SHANGHAI UNIV OF T C M
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com